



TB WORKS IN PROGRESS SERIES

THE UNIQUE ROLE OF CRISPR DIAGNOSTICS IN BLOOD-BASED TUBERCULOSIS DETECTION

KURT WEHRLE, MBA

Kurt Wehrle is Vice President of Partnerships & Strategic Alliances at IntelliGenome, bringing over 20 years of experience across in-vitro diagnostics. His current work focuses on the commercialization of the CRISPR-TB test, a blood-based diagnostic approach that has received FDA Breakthrough Device Designation, through collaboration with academic, clinical, and public-health stakeholders. He holds an MBA from the University of Chicago and a B.S. in Chemical Engineering.



Friday February 13, 2026



9 - 10 am



Virtual via Zoom

<https://zoom.us/j/95063270466>